Skip to main content
. 2022 Aug 15;132(16):e161065. doi: 10.1172/JCI161065

Figure 7. PET/CT imaging of 68Ga-grazytracer and 18F-FDG in patients with lung cancer.

Figure 7

(A) A 66-year-old male (patient 1) with lung adenocarcinoma, clinical stage cT2bN2M0 (IIIa). 18F-FDG PET/CT before 3 cycles of chemotherapy and anti–PD-1 therapy (pemetrexed disodium + cisplatin + toripalimab) showed that the SUVmax was 8.5 and the SULpeak was 5.3. 18F-FDG PET/CT after treatment showed that the SUVmax was 6.5 and the SULpeak was 3.8; this patient was rated as PMR (with EORTC criteria) and SMD (with PERCIST criteria). 68Ga-grazytracer PET/CT after treatment revealed a SUVmax of 4.1 and tumor-to-blood pool SUVmax ratio (T/B ratio) of 1.2, and the patient was assessed as having positive results. (B) IHC staining of granzyme B in the tumor of patient 1 before and after treatment. (C) IHC staining of PD-L1 in the tumor of patient 1 before treatment. Scale bars: 100 μm. (D) A 70-year-old male (patient 3) with sarcomatoid carcinoma of the lung, clinical stage cT4N3M1c (IVb). 18F-FDG PET/CT before 1 cycle of pembrolizumab revealed a SUVmax of 39.3 and SULpeak of 25.0. 18F-FDG PET/CT after treatment revealed a SUVmax of 26.4 and SULpeak of 16.6; this patient was rated as PMD (with EORTC and PERCIST criteria). 68Ga-grazytracer PET/CT after treatment showed that the SUVmax was 2.0 and T/B ratio was 0.8, and the patient was assessed as having negative results. (E and F) IHC staining of granzyme B (E) and PD-L1 (F) in the tumor of patient 3 before treatment. Scale bars: 100 μm. Primary tumors are indicated by the red arrows in PET images.